<?xml version="1.0" encoding="UTF-8"?><meta xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns="http://www.w3.org/1999/xhtml" xmlns:xi="http://www.w3.org/2001/XInclude" http-equiv="Content-Type" content="text/html; charset=utf-8" />
<style xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:xi="http://www.w3.org/2001/XInclude" type="text/css">
   @media screen{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .tds_obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:95%
   }
   .test-story-main table tbody tr td{
   font-size: 110%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   font-size:100%;
   }
   .test-story-main fieldset{
   text-align:center;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   
   }
   .test-story-main table th{
   border:2px groove;
   
   }
   .test-story-main table td{
   border:1px groove;
   
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:center;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .title{
   text-align:left;
   }
   .test-story-main h3{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .pgBrk{
   padding-top:15px;
   }
   .test-story-main .er7Msg{
   width:100%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
   
   @media print{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:90%
   }
   .test-story-main table tbody tr td{
   font-size:90%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   
   }
   .test-story-main table thead tr th{
   text-align:center;
   background:#4682B4;
   
   }
   .test-story-main fieldset{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   page-break-inside:avoid;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   }
   .test-story-main table th{
   border:2px groove;
   }
   .test-story-main table td{
   border:1px groove;
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:left;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left;
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .tds_title{
   text-align:left;
   margin-bottom:1%
   }
   .test-story-main h3{
   text-align:center;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .tds_pgBrk{
   page-break-after:always;
   }
   .test-story-main #er7Message table{
   border:0px;
   width:80%
   }
   .test-story-main #er7Message td{
   background:#B8B8B8;
   font-size:65%;
   margin-top:6.0pt;
   border:0px;
   text-wrap:preserve-breaks;
   white-space:pre;
   }
   .test-story-main .er7Msg{
   width:100%;
   font-size:80%;
   }
   .test-story-main .er7MsgNote{
   width:100%;
   font-style:italic;
   font-size:80%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .embSubSpace{
   padding-left:25px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
</style>
<!-- generated by TestStory_v1.xslt Version:1.0   Profile:TestStory-->
<fieldset>
	<div class="test-story-main">
		<tabset>
			<tab heading="FULL"  vertical="false">
				<div class="panel-body">
					<div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p><span style="font-size: 13.3333px;">The provider receives a vaccine delivery and records the new vaccine data in available inventory.</span></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Comments</th></tr><tr><td><p><span style="font-size: 13.3333px;">Set-up step evaluating EMR functions for capturing and storing vaccine inventory data.</span></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>No PreCondition</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p><span style="font-size: 13.3333px;">Vaccine inventory is recorded and available in the EMR.</span></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p><span style="font-size: 13.3333px; font-weight: bold; font-style: italic;">Update Vaccine Inventory from Stock Receipt:</span><span style="font-size: 13.3333px;">&nbsp;The EHR or other clinical software system updates the vaccine inventory when new stock is received at the site and updates the correct count of each vaccine, including those for use in guarantee programs (such as Vaccines for Children) and for private stock.</span></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p><span style="font-size: 13.3333px; font-family: Arial, Verdana; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: normal;">Vendor successfully records all vaccine inventory data provided:</span></p><div style="font-size: 10pt; font-family: Arial, Verdana; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: normal;"><span style="font-size: 13.3333px;"><br></span></div><p>1. Manufacturer:<span>&nbsp;</span>Sanofi Pasteur Inc.<br>NDC:49281-0413-58<br>Product Name:FLUZONE QUADRIVALENT<br>Lot#:D8043IN8422<br>Expiration Date:12/31/2019<br>Vaccine source:VFC<br>Quantity:15 Vials (or doses)</p><p>2. Manufacturer: GlaxoSmithKline Biologicals SA<br>NDC:58160-0881-41<br>Product Name:FLUARIX<br>Lot#: 8L4B3521<br>Expiration Date:12/31/2019<br>Vaccine source:VFC<br>Quantity:12 Vials (or doses)</p><p>3. Manufacturer:<span>&nbsp;</span>Sanofi Pasteur Inc.<br>NDC:49281-0413-58<br>Product Name:FLUZONE QUADRIVALENT<br>Lot#:D8043IN8855</p><p>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:12 Vials (or doses)</p><p>4. Manufacturer:<span>&nbsp;</span>GlaxoSmithKline Biologicals SA<br>NDC:58160-0820-43<br>Product Name:hepatitis B vaccine, pediatric or pediatric/adolescent dosage (CVX 08) ENGERIX-B (NDC 58160-0820-43)<br>Lot#:6332FK18<br>Expiration Date:6/15/2018<br>Vaccine source:Non-VFC<br>Quantity:18<span>&nbsp;</span>Syringes (or doses)</p><p>5. Manufacturer:<span>&nbsp;</span>GlaxoSmithKline Biologicals SA<br>NDC:58160-0820-43<br>Product Name:hepatitis B vaccine, pediatric or pediatric/adolescent dosage (CVX 08) ENGERIX-B (NDC 58160-0820-43)<br>Lot#:6332FK26<br>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:20 Syringes (or doses)</p><p>6. Manufacturer:<span>&nbsp;</span>GlaxoSmithKline Biologicals SA<br>NDC:58160-0811-43<br>Product Name:DTaP-hepatitis B and poliovirus vaccine (CVX 110) Pediarix (NDC 58160-0811-43)<br>Lot#:6559FK32<br>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:16<span>&nbsp;</span>Syringes (or doses)</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Notes</th></tr><tr><td><p><span style="font-size: 13.3333px;">This test step is introduced in 2018 and will be considered an evaluation year for the test step. Tester should document feedback and issues.</span></p><div><span style="font-size: 13.3333px;"><br></span></div><div><span style="font-size: 13.3333px;">Tester may provide 2-D barcode images as a data input option.</span></div></td></tr></table></div><br/>
				</div>
			</tab>
			<tab heading="Description" vertical="false"><div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p><span style="font-size: 13.3333px;">The provider receives a vaccine delivery and records the new vaccine data in available inventory.</span></p></td></tr></table></div></tab><tab heading="Comments" vertical="false"><div class="panel-body"><table><tr><th>Comments</th></tr><tr><td><p><span style="font-size: 13.3333px;">Set-up step evaluating EMR functions for capturing and storing vaccine inventory data.</span></p></td></tr></table></div></tab><tab heading="Pre-condition" vertical="false"><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>No PreCondition</p></td></tr></table></div></tab><tab heading="Post-Condition" vertical="false"><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p><span style="font-size: 13.3333px;">Vaccine inventory is recorded and available in the EMR.</span></p></td></tr></table></div></tab><tab heading="Test Objectives" vertical="false"><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p><span style="font-size: 13.3333px; font-weight: bold; font-style: italic;">Update Vaccine Inventory from Stock Receipt:</span><span style="font-size: 13.3333px;">&nbsp;The EHR or other clinical software system updates the vaccine inventory when new stock is received at the site and updates the correct count of each vaccine, including those for use in guarantee programs (such as Vaccines for Children) and for private stock.</span></p></td></tr></table></div></tab><tab heading="Evaluation Criteria" vertical="false"><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p><span style="font-size: 13.3333px; font-family: Arial, Verdana; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: normal;">Vendor successfully records all vaccine inventory data provided:</span></p><div style="font-size: 10pt; font-family: Arial, Verdana; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: normal;"><span style="font-size: 13.3333px;"><br></span></div><p>1. Manufacturer:<span>&nbsp;</span>Sanofi Pasteur Inc.<br>NDC:49281-0413-58<br>Product Name:FLUZONE QUADRIVALENT<br>Lot#:D8043IN8422<br>Expiration Date:12/31/2019<br>Vaccine source:VFC<br>Quantity:15 Vials (or doses)</p><p>2. Manufacturer: GlaxoSmithKline Biologicals SA<br>NDC:58160-0881-41<br>Product Name:FLUARIX<br>Lot#: 8L4B3521<br>Expiration Date:12/31/2019<br>Vaccine source:VFC<br>Quantity:12 Vials (or doses)</p><p>3. Manufacturer:<span>&nbsp;</span>Sanofi Pasteur Inc.<br>NDC:49281-0413-58<br>Product Name:FLUZONE QUADRIVALENT<br>Lot#:D8043IN8855</p><p>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:12 Vials (or doses)</p><p>4. Manufacturer:<span>&nbsp;</span>GlaxoSmithKline Biologicals SA<br>NDC:58160-0820-43<br>Product Name:hepatitis B vaccine, pediatric or pediatric/adolescent dosage (CVX 08) ENGERIX-B (NDC 58160-0820-43)<br>Lot#:6332FK18<br>Expiration Date:6/15/2018<br>Vaccine source:Non-VFC<br>Quantity:18<span>&nbsp;</span>Syringes (or doses)</p><p>5. Manufacturer:<span>&nbsp;</span>GlaxoSmithKline Biologicals SA<br>NDC:58160-0820-43<br>Product Name:hepatitis B vaccine, pediatric or pediatric/adolescent dosage (CVX 08) ENGERIX-B (NDC 58160-0820-43)<br>Lot#:6332FK26<br>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:20 Syringes (or doses)</p><p>6. Manufacturer:<span>&nbsp;</span>GlaxoSmithKline Biologicals SA<br>NDC:58160-0811-43<br>Product Name:DTaP-hepatitis B and poliovirus vaccine (CVX 110) Pediarix (NDC 58160-0811-43)<br>Lot#:6559FK32<br>Expiration Date:12/31/2019<br>Vaccine source:Non-VFC<br>Quantity:16<span>&nbsp;</span>Syringes (or doses)</p></td></tr></table></div></tab><tab heading="Notes" vertical="false"><div class="panel-body"><table><tr><th>Notes</th></tr><tr><td><p><span style="font-size: 13.3333px;">This test step is introduced in 2018 and will be considered an evaluation year for the test step. Tester should document feedback and issues.</span></p><div><span style="font-size: 13.3333px;"><br></span></div><div><span style="font-size: 13.3333px;">Tester may provide 2-D barcode images as a data input option.</span></div></td></tr></table></div></tab>
		</tabset>
	</div>
</fieldset>